# Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes

> **NCT03421119** · PHASE3 · UNKNOWN · sponsor: **Cinnagen** · enrollment: 300 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Liraglutide 6 MG/ML Pen Injector
- **DRUG:** Metformin
- **DRUG:** Sulfonylurea/non-sulfonylurea insulin secretagogues

## Key facts

- **NCT ID:** NCT03421119
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-20
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2019-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03421119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03421119, "Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03421119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*